Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 108

Sort by

Sort Order Select

Journal Articles

Phase-I Study of ETA Receptor Antagonist Ambrisentan in Sickle Cell Disease

Abdullah Kutlar, MD, Jennifer Pollock, PhD, Steffen E. Meiler, MD, Ryan Harris, PhD CEP, FACSM, Xu Hongyan, PhD, Leigh Wells, MSN, Latanya Bowman, RN, Sharon Jones, BS, David M. Pollock, PhD

Blood (2019) 134 (Supplement_1): 617.

https://doi.org/10.1182/blood-2019-130036

Published: 2019

Journal Articles

Upfront Ixazomib Plus Dexamethasone Induce Promptly Hematological Response in Patients with Light-Chain Amyloidosis

Zheng Wei, MD, Yian Zhang, Jing Li, MD, Peng Liu, MD

Blood (2019) 134 (Supplement_1): 1908.

https://doi.org/10.1182/blood-2019-127023

Published: 2019

Journal Articles

Blinatumomab + Ponatinib for Relapsed Ph1-Positive Acute Lymphoblastic Leukemia: The French Experience

Marie-Anne Couturier, MD, Xavier Thomas, MD, Francoise Huguet, MD, Céline Berthon, MD PhD, Célestine Simand, MD, Yosr Hicheri, Mathilde Hunault, MD PhD, Patrice Chevallier, MD

Blood (2018) 132 (Supplement 1): 4014.

https://doi.org/10.1182/blood-2018-99-111546

Published: 2018

Journal Articles

Incidence and Predictors of Hepatic Veno-Occlusive Disease after Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation

Clinton Lewis, MD, Haesook T. Kim, PhD, Corey S. Cutler, MD MPH, John Koreth, MBBS, DPhil, Sarah Nikiforow, MD PhD, Mahasweta Gooptu, MD, Rizwan Romee, MD, Brett Glotzbecker, Prashant Nageshwar, MD, Edwin P. Alyea, III, MD, Joseph H. Antin, MD, Paul Richardson, Robert J. Soiffer, MD, Vincent T. Ho, MD

Blood (2018) 132 (Supplement 1): 3376.

https://doi.org/10.1182/blood-2018-99-113130

Published: 2018

Journal Articles

A New Prognostic Index for Waldenström Macroglobulinemia Based on a Multicenter Retrospective Study of the Japanese Society of Myeloma

Blood (2018) 132 (Supplement 1): 5320.

https://doi.org/10.1182/blood-2018-99-111649

Published: 2018

Journal Articles

NOVEL-1 st : Interim Analysis of a Non-Interventional, Multi-Center Observational Study to Assess the Safety and Efficacy of Nilotinib in Newly Diagnosed Patients with Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) in Taiwan

Hwang Wen-Li, MD, Shao-Min Han, MD, Shyuann-Yuh Lin, MD, Ming-Chih Chang, MD, Li-Yuan Bai, PhD, Pei-Ching Hsiao, MD, Ching-Yuan Kuo, Yeu-Chin Chen, MD, Ta-Chih Liu, MD PhD, Po-Nan Wang, MD, Jyh-Pyng Gau, MD, Yee-Ming Lee, PhD, Fan-Chen Ku, Jih-Luh Tang, MD

Blood (2018) 132 (Supplement 1): 3019.

https://doi.org/10.1182/blood-2018-99-112342

Published: 2018

Journal Articles

Comparative Risk Assessment of Imatinib, Nilotinib and Dasatinib in Randomized Controlled Trials: A Meta-Analysis

Ahmad Ghorab, MDMSc, Hagop M. Kantarjian, MD, Hesham Elhalawani, MD MS, Hoda Ahmed, MD MS, Ahmed Essam, MD, Omar Abdel-Rahman, MD PhD, Elias J. Jabbour, MD, Jorge E. Cortes, MD

Blood (2017) 130 (Supplement 1): 2869.

https://doi.org/10.1182/blood.V130.Suppl_1.2869.2869

Published: 2017

Journal Articles

Perioperative Management of Von Willebrand Disease: An Institutional Experience

Craig D. Seaman, Margaret V. Ragni, MD MPH

Blood (2017) 130 (Supplement 1): 1081.

https://doi.org/10.1182/blood.V130.Suppl_1.1081.1081

Published: 2017

Journal Articles

Breaking bad…proteins

Donna E. Reece

Blood (2017) 129 (15): 2041–2042.

https://doi.org/10.1182/blood-2017-02-765560

Published: 2017

Journal Articles

A phase 2 trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis

Giovanni Palladini, Paolo Milani, Andrea Foli, Marco Basset, Francesca Russo, Stefano Perlini, Giampaolo Merlini

Blood (2017) 129 (15): 2120–2123.

https://doi.org/10.1182/blood-2016-12-756528

Published: 2017

Includes: Supplemental data

Journal Articles

Cardiotoxicity Secondary to Tyrosine Kinase Inhibitors 2nd Generation in Mexican Patients with Chronic Myeloid Leukemia

Manuel Ayala, MD, Jacqueline Domínguez, NL, Iván Bonilla, MD

Blood (2016) 128 (22): 5430.

https://doi.org/10.1182/blood.V128.22.5430.5430

Published: 2016

Journal Articles

Efficacy and Safety of Nilotinib 300 Mg Twice Daily (BD) in Patients with CML in Chronic Phase (CML-CP) Who Are Intolerant to Prior BCR-ABL Tyrosine Kinase Inhibitors (TKIs): Results from the Randomized, Phase IIIb E.N.E.S.Tswift Study

Devendra K Hiwase, MBBS, MD FRACP, FRCPA, PhD, Peter Tan, James D'Rozario, John Taper, MBBS FRACP FRCPA, Anthony Richard Powell, FRACP, MBBS, Ian Irving, Matthew P.F. Wright, MBBS, FRCPA, FRACP, Susan Branford, PhD FFSc (RCPA), David T. Yeung, BSc, MBBS, FRACP, FRCPA, Luke Anderson, Othon L Gervasio, Timothy P. Hughes, MD

Blood (2016) 128 (22): 5447.

https://doi.org/10.1182/blood.V128.22.5447.5447

Published: 2016

Journal Articles

A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) Versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients with AL Amyloidosis

Blood (2016) 128 (22): 646.

https://doi.org/10.1182/blood.V128.22.646.646

Published: 2016

Journal Articles

Discontinuation of Nilotinib in Patients with Chronic Myeloid Leukemia Who Have Maintained Deep Molecular Responses for at Least 2 Years: A Multicenter Phase 2 Stop Nilotinib (Nilst) Trial

Norimitsu Kadowaki, MD PhD, Tatsuya Kawaguchi, MD PhD, Junya Kuroda, MD PhD, Hirohisa Nakamae, MD PhD, Itaru Matsumura, MD PhD, Toshihiro Miyamoto, MD PhD, Jun Ishikawa, MD PhD, Koji Nagafuji, MD PhD, Yutaka Imamura, MD PhD, Hirohito Yamazaki, Mototsugu Shimokawa, PhD, Koichi Akashi, MD PhD, Yuzuru Kanakura, MD PhD

Blood (2016) 128 (22): 790.

https://doi.org/10.1182/blood.V128.22.790.790

Published: 2016

Journal Articles

Assessment of Quality of Life in the NCRI Spirit 2 Study Comparing Imatinib with Dasatinib in Patients with Newly-Diagnosed Chronic Phase Chronic Myeloid Leukaemia

Alexander M. Labeit, MDPhD, Mhairi Copland, BSc (Hons) MB ChB PhDFRCP FRCPath, Leanne M. Cork, BSc (Hons), Corinne A. Hedgley, BSc (Hons), Letizia Foroni, MDPhDFRCPath, Wendy L. Osborne, MBBS (Hons) MRCP FRCPath, Gemma Gills, MSc BSc (Hons), Jane F. Apperley, MD, Tessa L. Holyoake, MDPhD, Ruth V. Bescoby, MSc BSc, Christopher Pocock, Thomas Zwingers, MSc, Philippa Burnell, Jenny L. Byrne, PhD, John H. McCullough, John M. Goldman, DM FRCP FRCPath, Richard E. Clark, MD, Stephen G. O'Brien, BSc (Hons) PhD MBChB FRCP MRCPath

Blood (2015) 126 (23): 4024.

https://doi.org/10.1182/blood.V126.23.4024.4024

Published: 2015

Journal Articles

Fluid Overload As New Toxicity Category Has a Strong Impact on Non Relapse Mortality and Survival in Allogeneic Hematopoietic Stem Cell Transplantation

Gabriela Rondon, MD, Rima M Saliba, PhD, Julianne Chen, Celina Ledesma, Amin M. Alousi, MD, Betul Oran, MD, Chitra M. Hosing, MD, Partow Kebriaei, MD, Issa F. Khouri, Elizabeth J. Shpall, MD, Uday R. Popat, MD, Richard E. Champlin, MD, Stefan O. Ciurea, MD

Blood (2015) 126 (23): 4321.

https://doi.org/10.1182/blood.V126.23.4321.4321

Published: 2015

Journal Articles

Prior Use of Mogamulizumab to Allogenic Hematopoietic Stem Cell Transplantation Induces Severe Acute Graft-Versus-Host Disease

Blood (2015) 126 (23): 1940.

https://doi.org/10.1182/blood.V126.23.1940.1940

Published: 2015

Journal Articles

Drug Toxicities in Second-Line Treatment of Chronic Myeloid Leukemia

Tarcila S Datoguia, MD, Hugo R C Silva, MD, Amauri M C R Junior, MD, José Salvador Oliveira, PhD, Monika Conchon, MD PhD

Blood (2015) 126 (23): 5173.

https://doi.org/10.1182/blood.V126.23.5173.5173

Published: 2015

Journal Articles

Hypoalbuminemia Is Significantly Associated with Increased Clearance Time of High Doses of Methotrexate

Samantha N. Reiss, PharmD, Larry W. Buie, PharmD, BCOP, Nelly G. Adel, PharmD, BCOP, BCPS, Debra A. Goldman, MS, Sean Devlin, PhD, Dan Douer, MD

Blood (2015) 126 (23): 3711.

https://doi.org/10.1182/blood.V126.23.3711.3711

Published: 2015

Journal Articles

Phase 1 Study Results of a Novel Controlled-Release Formulation of Anagrelide (GALE-401) for the Treatment of Thrombocytosis

Robert J. Laliberte, MS, Paul F. Glidden, PhD, Brian L. Hamilton, MD PhD

Blood (2014) 124 (21): 3178.

https://doi.org/10.1182/blood.V124.21.3178.3178

Published: 2014

NARROW

Phase-I Study of ETA Receptor Antagonist Ambrisentan in Sickle Cell Disease

Upfront Ixazomib Plus Dexamethasone Induce Promptly Hematological Response in Patients with Light-Chain Amyloidosis

Blinatumomab + Ponatinib for Relapsed Ph1-Positive Acute Lymphoblastic Leukemia: The French Experience

Incidence and Predictors of Hepatic Veno-Occlusive Disease after Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation

A New Prognostic Index for Waldenström Macroglobulinemia Based on a Multicenter Retrospective Study of the Japanese Society of Myeloma

NOVEL-1 st : Interim Analysis of a Non-Interventional, Multi-Center Observational Study to Assess the Safety and Efficacy of Nilotinib in Newly Diagnosed Patients with Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) in Taiwan

Comparative Risk Assessment of Imatinib, Nilotinib and Dasatinib in Randomized Controlled Trials: A Meta-Analysis

Perioperative Management of Von Willebrand Disease: An Institutional Experience

Breaking bad…proteins

A phase 2 trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis

Cardiotoxicity Secondary to Tyrosine Kinase Inhibitors 2nd Generation in Mexican Patients with Chronic Myeloid Leukemia

Efficacy and Safety of Nilotinib 300 Mg Twice Daily (BD) in Patients with CML in Chronic Phase (CML-CP) Who Are Intolerant to Prior BCR-ABL Tyrosine Kinase Inhibitors (TKIs): Results from the Randomized, Phase IIIb E.N.E.S.Tswift Study

A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) Versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients with AL Amyloidosis

Discontinuation of Nilotinib in Patients with Chronic Myeloid Leukemia Who Have Maintained Deep Molecular Responses for at Least 2 Years: A Multicenter Phase 2 Stop Nilotinib (Nilst) Trial

Assessment of Quality of Life in the NCRI Spirit 2 Study Comparing Imatinib with Dasatinib in Patients with Newly-Diagnosed Chronic Phase Chronic Myeloid Leukaemia

Fluid Overload As New Toxicity Category Has a Strong Impact on Non Relapse Mortality and Survival in Allogeneic Hematopoietic Stem Cell Transplantation

Prior Use of Mogamulizumab to Allogenic Hematopoietic Stem Cell Transplantation Induces Severe Acute Graft-Versus-Host Disease

Drug Toxicities in Second-Line Treatment of Chronic Myeloid Leukemia

Hypoalbuminemia Is Significantly Associated with Increased Clearance Time of High Doses of Methotrexate

Phase 1 Study Results of a Novel Controlled-Release Formulation of Anagrelide (GALE-401) for the Treatment of Thrombocytosis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only